ClinicalTrials.gg
CompletedNCT02033889Updated Sep 10, 2018Results posted

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
621
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
4th of 28
621 · median 83
Started
2013
with 5 others
Phase 3
11 of 28
none open now
Registered
12th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo.

Read the detailed description

The trial includes a 13-15 week run-in period prior to randomization, and a 26-week, double-blind, placebo-controlled treatment period followed by a 78-week double-blind, extension period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T2DM in accordance to American Diabetes Association guidelines
  • Participants must be receiving metformin monotherapy for less than 8 weeks prior to study participation or require change in their diabetes regimen to remain eligible to participate in the trial (including discontinuing anti-hyperglycemic agent [AHA] therapy) and must have a of 7.0 to 10.5% (53-91 mmol/mol) after at least 8 weeks on a regimen of metformin monotherapy

Exclusion criteria

Exclusion Criteria:

  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study participation
  • A abnormality
  • A history of ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer
  • A known or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor or glimepiride
  • On a blood pressure or lipid altering medication that have not been on a stable dose for at least 4 weeks prior to study participation
  • A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial
  • Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial
  • Pregnant or breast-feeding, or is expecting to conceive during the trial, including 14 days following the last dose of study drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
621 participants (actual)

Study arms

  • Experimental
    Ertuglifozin 5 mg

    Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.

    Drug: Ertugliflozin 5 mg · Drug: Placebo to Ertugliflozin · Other: Glimepiride · Drug: Placebo to Glimepiride · Biological: Basal Insulin · Drug: Metformin

  • Experimental
    Ertugliflozin 15 mg

    Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.

    Drug: Ertugliflozin 15 mg · Other: Glimepiride · Drug: Placebo to Glimepiride · Biological: Basal Insulin · Drug: Metformin

  • Placebo comparator
    Placebo/Glimepiride

    Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.

    Drug: Placebo to Ertugliflozin · Other: Glimepiride · Biological: Basal Insulin · Drug: Metformin

Interventions

  • Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.

    Also known as: MK-8835

  • Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.

    Also known as: MK-8835

  • DrugPlacebo to Ertugliflozin

    Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.

  • OtherGlimepiride

    Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.

    Also known as: Amaryl, GLIMPID, GLIMY

  • DrugPlacebo to Glimepiride

    Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.

  • BiologicalBasal Insulin

    Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.

    Also known as: Insulin glargine, Insulin detemir, NPH insulin, Degludec

  • Metformin \>=1500 mg/day, orally, once a day

    Also known as: Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor, Metfogamma

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.

    Time frame: Up to Week 106

  3. Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.

    Time frame: Up to Week 104

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

    The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  3. Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 26

  4. Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

    This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  5. Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

    This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  6. Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 26

  7. Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

    Time frame: Up to Week 26

  8. Time to Glycemic Rescue Therapy at Week 26

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

    Time frame: Week 26

  9. Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 52

  10. Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 52

  11. Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 52

  12. Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 52

  13. Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52

    Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

    Time frame: Up to Week 52

  14. Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)

    The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 52

  15. Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)

    This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 52

  16. Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)

    This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 52

  17. Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 104

  18. Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 104

  19. Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 104

  20. Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Week 104

  21. Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104

    Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

    Time frame: Up to Week 104

  22. Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)

    The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 104

  23. Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)

    This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 104

  24. Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)

    This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 104

  25. Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)

    Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

    Time frame: Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30

  26. Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  27. Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  28. Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  29. Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  30. Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)

    CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  31. Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)

    P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  32. Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)

    PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 26

  33. Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  34. Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  35. Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  36. Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  37. Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)

    CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  38. Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)

    P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  39. Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)

    PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 52

  40. Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

  41. Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

  42. Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

  43. Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

    BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

  44. Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)

    CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

  45. Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)

    P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

  46. Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)

    PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

    Time frame: Baseline and Week 104

07

Results

Posted Sep 10, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Started209207205
Completed175187180
Not completed342025
Withdrew: Adverse event313
Withdrew: Death312
Withdrew: Excluded medication110
Withdrew: Lost to follow-up856
Withdrew: Non-compliance with study drug100
Withdrew: Physician decision011
Withdrew: Participant moved010
Withdrew: Withdrawal by subject181013

Outcome measures

PrimaryChange From Baseline in A1C at Week 26 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent A1C
Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)
Percent A1CPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)-0.03 (-0.15 to 0.10)-0.73 (-0.85 to -0.61)-0.91 (-1.03 to -0.78)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -0.88 · 95% CI -1.05 to -0.71
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -0.70 · 95% CI -0.87 to -0.53
PrimaryPercentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.

Time frame:
Up to Week 106
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)77.570.575.6
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.

Time frame:
Up to Week 104
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)2.43.43.9
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in % vs placebo/glimepiride: 1.5 · 95% CI -2.1 to 5.4
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in % vs placebo/glimepiride: 1.0 · 95% CI -2.5 to 4.7
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
mg/dLPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)-0.85 (-5.93 to 4.23)-27.54 (-32.36 to -22.73)-39.10 (-43.96 to -34.23)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -38.25 · 95% CI -44.50 to -31.99
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in the least squares means: -26.69 · 95% CI -32.90 to -20.48
SecondaryChange From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
KilogramsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)-1.33 (-1.74 to -0.92)-3.01 (-3.40 to -2.62)-2.93 (-3.33 to -2.53)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -1.60 · 95% CI -2.16 to -1.03
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -1.67 · 95% CI -2.24 to -1.11
SecondaryPercentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)15.835.340.0
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Regression, Logistic · p = <0.001 · Adjusted odds ratio relative to placebo: 4.48 · 95% CI 2.64 to 7.62
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Regression, Logistic · p = <0.001 · Adjusted odds ratio relative to placebo: 3.03 · 95% CI 1.81 to 5.06
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
mmHgPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)-0.70 (-2.46 to 1.06)-4.38 (-6.01 to -2.75)-5.20 (-6.87 to -3.54)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Constrained Longitudinal Data Analysis · p = <0.001 · Difference in least squares means: -4.50 · 95% CI -6.81 to -2.19
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Constrained Longitudinal Data Analysis · p = 0.002 · Difference in least squares means: -3.68 · 95% CI -5.96 to -1.39
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
mmHgPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)0.23 (-0.85 to 1.31)-1.59 (-2.59 to -0.59)-2.19 (-3.21 to -1.17)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Constrained Longitudinal Data Analysis · p = 0.001 · Difference in least squares means: -2.42 · 95% CI -3.86 to -0.98
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Constrained Longitudinal Data Analysis · p = 0.013 · Difference in least squares means: -1.82 · 95% CI -3.24 to -0.39
SecondaryPercentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)2.98.712.2
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Regression, Logistic · p = <0.001 · Adjusted odds ratio: 5.41 · 95% CI 2.10 to 13.90
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Regression, Logistic · p = 0.023 · Adjusted odds ratio: 3.10 · 95% CI 1.17 to 8.22
SecondaryPercentage of Participants Receiving Glycemic Rescue Therapy up to Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

Time frame:
Up to Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 2617.72.91.5
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Miettinen & Nurminen method · p = <0.001 · Difference in % vs placebo: -16.2 · 95% CI -22.2 to -11.2Miettinen \& Nurminen method was used to construct both the 95% CI and derive p-value for the difference between the proportions (i.e. percentages).
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Miettinen & Nurminen method. · p = <0.001 · Difference in % vs placebo: -14.8 · 95% CI -20.9 to -9.4Miettinen \& Nurminen method was used to construct both the 95% CI and derive p-value for the difference between the proportions (i.e. percentages).
SecondaryTime to Glycemic Rescue Therapy at Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

Time frame:
Week 26
Reported as:
Median · Days
Time to Glycemic Rescue Therapy at Week 26
DaysPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Time to Glycemic Rescue Therapy at Week 26105 (15 to 183)112 (23 to 151)139 (127 to 145)
SecondaryChange From Baseline in A1C at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent A1C
Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)
Percent A1CPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)-0.68 ± 0.99-0.72 ± 0.95-0.96 ± 0.88
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)
mg/dLPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)-12.0 ± 40.0-22.4 ± 39.3-35.2 ± 40.7
SecondaryPercentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)30.634.836.6
SecondaryPercentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)11.010.614.6
SecondaryPercentage of Participants Receiving Glycemic Rescue Therapy up to Week 52

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 5217.2 (12.37 to 23.04)4.3 (2.01 to 8.09)1.5 (0.3 to 4.22)
SecondaryChange From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)
KilogramsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)0.07 ± 2.85-3.23 ± 3.68-3.35 ± 3.27
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)
mmHgPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)0.65 ± 13.38-2.63 ± 14.40-4.28 ± 13.28
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 52
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)
mmHgPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)0.38 ± 8.16-1.40 ± 9.60-1.19 ± 7.74
SecondaryChange From Baseline in A1C at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 104
Reported as:
Mean · Percent A1C
Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)
Percent A1CPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)-0.58 ± 0.93-0.60 ± 0.97-0.89 ± 0.90
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 104
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)
mg/dLPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)-10.9 ± 44.3-18.2 ± 43.5-28.2 ± 44.9
SecondaryPercentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 104
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)19.124.633.7
SecondaryPercentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Week 104
Reported as:
Number · Percentage of Participants
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)
Percentage of ParticipantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)7.210.612.2
SecondaryPercentage of Participants Receiving Glycemic Rescue Therapy up to Week 104

Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.

Time frame:
Up to Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104
Percentage of participantsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 10424.4 (18.74 to 30.8)11.1 (7.18 to 16.2)10.7 (6.85 to 15.8)
SecondaryChange From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 104
Reported as:
Mean · Kilograms
Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)
KilogramsPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)-0.18 ± 3.38-3.77 ± 4.29-3.63 ± 3.86
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 104
Reported as:
Mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)
mmHgPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)0.05 ± 13.76-3.61 ± 12.78-3.13 ± 14.11
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 104
Reported as:
Mean · mmHg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)
mmHgPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)-0.46 ± 8.77-2.36 ± 9.23-1.52 ± 8.61
SecondaryErtugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)

Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.

Time frame:
Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30
Reported as:
Mean · ng/mL
Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)
ng/mLPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Week 6:Pre-doseNA ± NA14.89 ± 28.1138.38 ± 74.83
Week 12:Pre-doseNA ± NA12.34 ± 26.0729.23 ± 55.63
Week 12:60 mins post-doseNA ± NA74.84 ± 51.58228.13 ± 139.14
Week 18:Pre-dose0.01 ± 0.109.91 ± 21.1824.46 ± 39.97
Week 18:60 mins post-dose0.01 ± 0.0974.39 ± 49.77214.96 ± 147.36
Week 30:Pre-dose0.15 ± 1.0712.66 ± 25.5030.55 ± 60.33
SecondaryPercent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage change
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
Percentage changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)0.22 (-0.20 to 0.65)-0.01 (-0.42 to 0.41)0.12 (-0.31 to 0.55)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: -0.10 · 95% CI -0.71 to 0.50
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.23 · 97% CI -0.83 to 0.37
SecondaryPercent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)-0.40 (-0.89 to 0.09)-0.10 (-0.57 to 0.38)0.30 (-0.19 to 0.79)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: 0.70 · 95% CI 0.00 to 1.39
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: 0.30 · 95% CI -0.38 to 0.99
SecondaryPercent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)-0.63 (-0.92 to -0.34)-0.55 (-0.83 to -0.27)-0.36 (-0.65 to -0.07)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: 0.27 · 95% CI -0.15 to 0.68
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: 0.08 · 95% CI -0.33 to 0.48
SecondaryPercent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)0.06 (-0.35 to 0.47)-0.15 (-0.55 to 0.24)-0.13 (-0.53 to 0.28)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: -0.19 · 95% CI -0.76 to 0.39
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.21 · 95% CI -0.78 to 0.35
SecondaryPercent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)10.8 ± 106.651.9 ± 121.980.2 ± 149.7
SecondaryPercent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)0.5 ± 11.70.8 ± 12.10.5 ± 15.0
SecondaryPercent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 26
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)-0.98 ± 6.710.28 ± 7.520.14 ± 7.53
SecondaryPercent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)-0.10 (-0.60 to 0.40)-0.28 (-0.77 to 0.20)0.07 (-0.43 to 0.57)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: 0.17 · 95% CI -0.53 to 0.88
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.18 · 97% CI -0.88 to 0.51
SecondaryPercent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)-0.69 (-1.25 to -0.14)-0.49 (-1.04 to 0.06)-0.44 (-1.06 to 0.17)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: 0.25 · 95% CI -0.48 to 0.98
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: 0.20 · 95% CI -0.51 to 0.91
SecondaryPercent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)-0.82 (-1.19 to -0.46)-1.04 (-1.41 to -0.67)-1.32 (-1.69 to -0.94)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: -0.50 · 95% CI -0.95 to -0.04
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.22 · 95% CI -0.66 to 0.23
SecondaryPercent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)-0.44 (-0.95 to 0.06)-0.59 (-1.04 to 0.14)-0.39 (-0.90 to 0.12)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: 0.06 · 95% CI -0.61 to 0.72
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.15 · 95% CI -0.78 to 0.49
SecondaryPercent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)15.54 ± 43.3434.36 ± 52.7441.57 ± 50.69
SecondaryPercent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent Change
Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)
Percent ChangePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)24.50 ± 120.298.41 ± 30.9519.79 ± 79.57
SecondaryPercent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent Change
Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)
Percent ChangePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)8.11 ± 52.0511.09 ± 41.802.48 ± 36.57
SecondaryPercent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)0.09 (-0.47 to 0.66)-0.19 (-0.72 to 0.35)-0.13 (-0.68 to 0.42)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: -0.23 · 95% CI -1.01 to 0.56
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.28 · 97% CI -1.06 to 0.50
SecondaryPercent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)-1.23 (-1.86 to -0.61)-1.11 (-1.74 to -0.49)-0.96 (-1.67 to -0.26)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: 0.27 · 95% CI -0.58 to 1.13
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: 0.12 · 95% CI -0.70 to 0.93
SecondaryPercent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)-1.18 (-1.63 to -0.73)-1.72 (-2.19 to -1.25)-2.02 (-2.51 to -1.53)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: -0.84 · 95% CI -1.44 to -0.24
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: -0.54 · 95% CI -1.12 to 0.05
SecondaryPercent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Least squares mean · Percent change
Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)-0.58 (-1.13 to -0.03)-0.40 (-0.87 to 0.06)-0.64 (-1.19 to -0.09)
Statistical analysis
  • Placebo/Glimepiride vs Ertugliflozin 15 mg · Difference in the least squares means: -0.06 · 95% CI -0.77 to 0.65
  • Placebo/Glimepiride vs Ertugliflozin 5 mg · Difference in the least squares means: 0.18 · 95% CI -0.50 to 0.85
SecondaryPercent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)19.29 ± 71.7326.94 ± 58.4432.53 ± 59.29
SecondaryPercent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)19.38 ± 93.0210.11 ± 39.1424.21 ± 83.23
SecondaryPercent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.

Time frame:
Baseline and Week 104
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)
Percent changePlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)10.12 ± 60.138.16 ± 40.975.46 ± 38.53

Adverse events

Collected over Up to 106 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Glimepiride3/209 (1.4%)22/209 (10.5%)103/209 (49.3%)
Ertugliflozin 5 mg1/207 (0.5%)20/207 (9.7%)79/207 (38.2%)
Ertugliflozin 15 mg2/205 (1%)20/205 (9.8%)100/205 (48.8%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
Peripheral ischaemiaVascular disorders0/2090/2072/205
Angina unstableCardiac disorders0/2092/2071/205
Atrial fibrillationCardiac disorders0/2092/2071/205
Myocardial infarctionCardiac disorders1/2092/2071/205
PancreatitisGastrointestinal disorders2/2090/2070/205
Cardiac failureCardiac disorders0/2090/2071/205
Myocardial ischaemiaCardiac disorders0/2090/2071/205
Sinus node dysfunctionCardiac disorders0/2090/2071/205
Myocardial bridgingCongenital, familial and genetic disorders0/2090/2071/205
PhimosisCongenital, familial and genetic disorders0/2090/2071/205
Most frequent other events
Most frequent other events
EventPlacebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mg
HypoglycaemiaMetabolism and nutrition disorders43/20914/20718/205
Upper respiratory tract infectionInfections and infestations33/20923/20721/205
Viral upper respiratory tract infectionInfections and infestations21/20912/2079/205
Back painMusculoskeletal and connective tissue disorders10/2099/20720/205
Urinary tract infectionInfections and infestations13/2096/20717/205
Weight decreasedInvestigations3/2099/20715/205
HeadacheNervous system disorders10/20914/20711/205
InfluenzaInfections and infestations12/20911/20710/205
ArthralgiaMusculoskeletal and connective tissue disorders7/2097/20711/205
CoughRespiratory, thoracic and mediastinal disorders11/2098/2078/205

Baseline characteristics

All randomized and treated participants

Age, Continuous
Age, Continuous(Years)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Mean56.5 ± 8.756.6 ± 8.256.9 ± 9.456.6 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Female111110112333
Male989793288
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
American Indian or Alaska Native0000
Asian313435100
Native Hawaiian or Other Pacific Islander0000
Black or African American19222364
White144134133411
More than one race15171446
Unknown or Not Reported0000
Baseline Hemoglobin A1C (A1C)
Baseline Hemoglobin A1C (A1C)(Percentage A1C)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Mean8.17 ± 0.908.06 ± 0.898.13 ± 0.938.12 ± 0.90
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Mean169.1 ± 41.7168.1 ± 45.5167.5 ± 44.4168.3 ± 43.8
Body Weight
Body Weight(Kilograms)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Mean84.5 ± 17.184.8 ± 17.285.3 ± 16.584.9 ± 16.9
Sitting Systolic Blood Pressure (SBP)
Sitting Systolic Blood Pressure (SBP)(mmHg)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Mean129.30 ± 15.43130.48 ± 13.77130.37 ± 12.00130.05 ± 13.80
Diastolic Blood Pressure (DBP)
Diastolic Blood Pressure (DBP)(mmHg)Placebo/GlimepirideErtugliflozin 5 mgErtugliflozin 15 mgTotal
Mean77.45 ± 7.5578.45 ± 8.3278.08 ± 7.4577.99 ± 7.78

9 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Rosenstock J, Frias J, Pall D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Erratum In: Diabetes Obes Metab. 2018 Nov;20(11):2708. doi: 10.1111/dom.13533. PubMed 28857451 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Cherney DZI, Heerspink HJL, Frederich R, Maldonado M, Liu J, Pong A, Xu ZJ, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020 Jun;63(6):1128-1140. doi: 10.1007/s00125-020-05133-4. Epub 2020 Mar 31. PubMed 32236732 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗
  • Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7. PubMed 31064361 ↗
  • Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019 Apr;21(4):1027-1036. doi: 10.1111/dom.13631. Epub 2019 Feb 14. PubMed 30614616 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Aug 2017, 43 months.

Results were first posted in Sep 2018, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 43 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2014
First posted
Jan 13, 2014
StartActual
Dec 13, 2013
Primary completionActual
Aug 3, 2017
CompletionActual
Aug 3, 2017
Results first posted
Sep 10, 2018
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02033889
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Dec 13, 2013
Primary completion
Aug 3, 2017
Completion
Aug 3, 2017
Results posted
Sep 10, 2018
Last update
Sep 10, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion